The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s Advair, AstraZeneca’s Symbicort) will be called into question, as new generic/branded-generic agents continue to launch over the next several years. In addition, the market entrance of LABA/LAMA/ICS FDCs could create uptake challenges for Boehringer Ingelheim’s Spiriva—which, despite notable previous off-label use, was only recently approved for asthma. Finally, the launch of novel biologics will fuel increasing competition and pricing pressure in the severe, refractory segment of the asthma market. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current—and emerging—asthma agents will be faced with increasing challenges to gain favorable formulary position and market uptake.
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.